Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

THE TRUTH ABOUT: 9 | History Defined

FDA says knockoff versions of Lilly obesity drug must come off the market

The federal government is phasing out off-brand copies of two blockbuster drugs used to treat obesity and diabetes

The Independent UK

Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon

Novo Nordisk A/S is moving closer to adding more sales for its blockbuster GLP-1 drug semaglutide to treat a chronic liver disease.

MarketBeat

Eli Lilly To Invest $3B To Expand Plant To Meet Surge In Demand For Weight Loss Drugs

Construction on the facility in Kenosha County, Wis., is expected to begin next year.

International Business Times

From analysis to the latest developments in health,
read the most diverse news in one place.

Eli Lilly Invests Billion In Manufacturing Expansion Projects

Eli Lilly invests billion to boost manufacturing capabilities, expanding in Wisconsin and Indianapolis to meet growing market demand.

Top News

Eli Lilly invests $3B to expand Wisconsin factory to help meet demand for Mounjaro, Zepbound

Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products

The Independent UK

Is Zepbound or Wegovy better for weight loss? New clinical trial reveals which medication sheds more pounds

Amid the war on obesity, a clear winner has emerged in a battle between two weight-loss injectables.

Fortune

Decoding Eli Lilly's Options Activity: What's the Big Picture?

Investors with a lot of money to spend have taken a bearish stance on Eli Lilly (NYSE:LLY).

Benzinga

Read news from The Economist, FT, and more,
with one subscription

3 Mega-Cap Stocks to Buy Before They're Worth $1 Trillion

These corporate giants could be the next entrants to the $1 trillion market cap club.

Barchart

Behind the Scenes of Eli Lilly's Latest Options Trends

Financial giants have made a conspicuous bearish move on Eli Lilly. Our analysis of options history for Eli Lilly (NYSE:LLY) revealed 8 unusual trades.

Benzinga

Tradepulse Power Inflow Alert: Eli Lilly & Company Climbs Over 22 Points After Alert

STOCK RISES OVER 2.8% AT ITS HIGH FOR THE DAY

Benzinga

2 Vaccine Stocks to Buy on the Dip

Given the cutting-edge pipeline for these two vaccine companies, double-digit slumps in these stocks present a compelling entry point for investors.

Barchart

Weight-Loss Drugmakers Press Companies To Cover Cost Of Treatment

The efforts by Eli Lilly and Novo Nordisk could be a game-changer for sales, which some analysts say could exceed $100 billion a year.

International Business Times

Lilly Sues US Agency For Blocking Proposed Drug Rebate Plan

Eli Lilly is taking the HRSA to court for allegedly blocking the pharma's discount plan.

International Business Times

Eli Lilly CEO's explains how failing fast leads to success

For Eli Lilly CEO Dave Ricks, speeding up the drug discovery process is essential to success.

Fortune

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Eli Lilly Stock: Is Wall Street Bullish or Bearish?

Eli Lilly has outperformed the broader market and its peers this year, and Wall Street analysts are bullish about the stock’s prospects.

The Guardian - UK

Approved weight-loss drug contributed to UK nurse’s death, report says

Susan McGowan took two doses of tirzepatide, under Mounjaro brand, before she died in North Lanarkshire

The National (Scotland)

Scottish nurse’s death linked to approved weight-loss drug

THE death of a Scottish nurse has been linked to a weight-loss drug approved on the NHS.

Barchart

Thanks to Wall Street, Novo Nordisk Stock is Now a Buy

Novo Nordisk has lost about a quarter of its value since the end of June. Meanwhile, indications are that its diabetes and weight-loss drugs may be useful in fighting cardiovascular disease, arthritis, opioid and alcohol addiction, and Alzheimer's. Novo remains a leader in the sector, and is trading at a…

Get all your
news in one place.

100's of premium titles.
One news app.

Evening Standard

Fact check: Weight loss drug trial, US election rules and ‘IDF soldiers’ image

Round up of fact checks from the last week compiled by Full Fact.

Barchart

3 Top Healthcare Stocks to Buy for Growth and Dividends

Investors seeking growth and dividend income in the healthcare sector may want to consider Eli Lilly, Gilead Sciences, and Amgen, which have delivered impressive returns and boast strong pipelines and strategic moves.

StockNews.com

Is Eli Lilly Still a Top Healthcare Stock After Its Blockbuster Drug Approval?

Pharmaceutical giant Eli Lilly and Company (LLY) is on an impressive run after winning Food and Drug Administration approval for a new eczema drug called Ebglyss. As the company expands its reach in the diabetes, obesity, and eczema markets, is it a must-have in your healthcare portfolio? Read on to…

Evening Standard

Alzheimer’s drug rejected for widespread use by NHS spending watchdog

Donanemab is a so-called disease-modifying treatment.

The National (Scotland)

Wes Streeting says weight-loss jabs for unemployed not 'dystopian'

THE UK’s Health Secretary has denied his plans to give weight-loss jabs to unemployed people would result in a “dystopian future”.

The Guardian - UK

Pumping the unemployed with weight-loss drugs echoes Victorian attitudes to the poor

Shifting blame to the victims of economic policy is an old trick by politicians. Now they’re using obesity to tackle joblessness

The National (Scotland)

Experts weigh in on Labour plan to offer weight loss jabs to unemployed

LABOUR plans to give obese and unemployed people weight-loss jabs as part of a drive to get them back into work and reduce pressure on the NHS…

1 … 8 9 10 11

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.